Assetmark Inc. raised its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 5.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 189,597 shares of the company's stock after buying an additional 10,014 shares during the quarter. Assetmark Inc.'s holdings in Sanofi were worth $10,515,000 at the end of the most recent reporting period.
Other hedge funds have also made changes to their positions in the company. Brighton Jones LLC boosted its holdings in Sanofi by 52.6% in the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company's stock valued at $261,000 after acquiring an additional 1,869 shares during the last quarter. Congress Wealth Management LLC DE purchased a new stake in shares of Sanofi during the fourth quarter worth about $378,000. Orion Portfolio Solutions LLC grew its stake in Sanofi by 10.7% in the fourth quarter. Orion Portfolio Solutions LLC now owns 71,179 shares of the company's stock worth $3,433,000 after purchasing an additional 6,893 shares in the last quarter. Intrust Bank NA grew its stake in Sanofi by 5.2% in the fourth quarter. Intrust Bank NA now owns 27,978 shares of the company's stock worth $1,349,000 after purchasing an additional 1,391 shares in the last quarter. Finally, Transamerica Financial Advisors Inc. grew its stake in Sanofi by 20.7% in the fourth quarter. Transamerica Financial Advisors Inc. now owns 5,747 shares of the company's stock worth $278,000 after purchasing an additional 987 shares in the last quarter. Institutional investors and hedge funds own 14.04% of the company's stock.
Sanofi Price Performance
Shares of NASDAQ SNY traded down $0.17 during trading on Wednesday, hitting $49.18. The company had a trading volume of 362,729 shares, compared to its average volume of 2,510,401. The company has a market cap of $120.60 billion, a P/E ratio of 17.57, a PEG ratio of 1.13 and a beta of 0.48. Sanofi has a 52 week low of $45.80 and a 52 week high of $60.12. The business's 50-day moving average is $49.42 and its 200 day moving average is $52.13. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.69 and a current ratio of 1.37.
Wall Street Analyst Weigh In
A number of equities analysts have commented on the company. Morgan Stanley set a $56.00 target price on Sanofi in a research note on Monday, June 2nd. Guggenheim reiterated a "buy" rating on shares of Sanofi in a research report on Tuesday, June 3rd. Hsbc Global Res upgraded Sanofi to a "strong-buy" rating in a research report on Monday, April 28th. BNP Paribas initiated coverage on Sanofi in a research report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price objective for the company. Finally, Barclays reiterated an "overweight" rating on shares of Sanofi in a research report on Wednesday, July 2nd. Three equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, Sanofi has an average rating of "Buy" and a consensus target price of $62.00.
Get Our Latest Stock Report on SNY
Sanofi Company Profile
(
Free Report)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Recommended Stories

Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.